CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Gastrointestinal stromal tumors (GIST) require improved prognostic factors and therapies to overcome imatinib resistance.
• The immune system offers a promising avenue for GIST treatment.
• CSPG4, a cell surface proteoglycan, is a potential target for cancer immunotherapy, including chimeric antigen receptor (CAR)-redirected cytokine-induced killer lymphocytes (CAR.CIKs).

Purpose of the Study:

• To investigate CSPG4 mRNA expression in GIST.
• To explore correlations between CSPG4 expression and clinicopathological and immune features in GIST.
• To assess the potential of CSPG4 as a therapeutic target for GIST immunotherapy.

Main Methods:

• Analysis of CSPG4 mRNA expression data from 309 clinical GIST samples using DNA microarrays.
• Correlation analysis with clinicopathological parameters (AFIP risk, tumor site, stage) and immune signatures.
• Evaluation of immune response indicators in tumors with high versus low CSPG4 expression.

Main Results:

• CSPG4 expression was higher in GIST tumors than normal digestive tissues and showed heterogeneity.
• High CSPG4 expression was associated with AFIP low-risk, gastric site, localized stage, and independently with longer disease-free survival (DFS) in localized GIST.
• CSPG4-high tumors exhibited a heightened anti-tumor immune response involving both adaptive and innate immunity.

Conclusions:

• High CSPG4 expression in GIST is linked to better DFS and a favorable immune microenvironment.
• CSPG4-targeted immunotherapies, such as CSPG4-CAR.CIKs, may enhance anti-tumor immunity in GIST.
• Combination therapies involving CSPG4-CAR.CIKs and immune checkpoint inhibitors could be beneficial for GIST treatment.